Simponi Aria

Simponi Aria is the intravenous version of the Simponi biologic. It has been approved by U.S. Food and Drug Administration for the treatment of psoriatic arthritis.

What is Simponi Aria?

Simponi Aria (also known by its generic name golimumab) is a a TNF-alpha inhibitor that was approved by the FDA in October 2017 to treat adults with active psoriatic arthritis. In September 2020, the indication was extended to include pediatric patients 2 years and older. Simponi Aria is also approved to treat rheumatoid arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.

For adults with active psoriatic arthritis, the Simponi Aria is given in a doctor's office as an intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter. For pediatric patients with psoriatic arthritis, the Simponi Aria is given in a doctor's office as an intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter.

To learn more, please visit the Simponi Aria website.

An intravenous drug closeup.

FDA Approves Intravenous Infusion Drug for Psoriatic Arthritis

Adults can treat PsA with Simponi Aria in as few as six treatments per year.

Discover more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Keep up to date with the psoriatic disease field.

Start reading

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.